

Monepantel is a non-competitive antagonist of nicotinic acetylcholine receptors from *Ascaris suum* and *Oesophagostomum dentatum*

Melanie Abongwa^{a,1}, Djordje S. Marjanovic^{b,1}, James G. Tipton^a, Fudan Zheng^{c,2}, Richard J. Martin^a, Sasa M. Trailovic^b, Alan P. Robertson^{a,*}

^a Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA

^b Department of Pharmacology and Toxicology, College of Veterinary Medicine, University of Belgrade, Belgrade, Serbia

^c Department of Chemistry, College of Liberal Arts and Sciences, Iowa State University, Ames, IA 50011, USA



ARTICLE INFO

Keywords:

Monepantel
Zolvix[®]
Nicotinic acetylcholine receptors
Mode of action
Non-competitive antagonist

ABSTRACT

Zolvix[®] is a recently introduced anthelmintic drench containing monepantel as the active ingredient. Monepantel is a positive allosteric modulator of DEG-3/DES-2 type nicotinic acetylcholine receptors (nAChRs) in several nematode species. The drug has been reported to produce hypercontraction of *Caenorhabditis elegans* and *Haemonchus contortus* somatic muscle. We investigated the effects of monepantel on nAChRs from *Ascaris suum* and *Oesophagostomum dentatum* heterologously expressed in *Xenopus laevis* oocytes. Using two-electrode voltage-clamp electrophysiology, we studied the effects of monepantel on a nicotine preferring homomeric nAChR subtype from *A. suum* comprising of ACR-16; a pyrantel/tribendimidine preferring heteromeric subtype from *O. dentatum* comprising UNC-29, UNC-38 and UNC-63 subunits; and a levamisole preferring subtype (*O. dentatum*) comprising UNC-29, UNC-38, UNC-63 and ACR-8 subunits. For each subtype tested, monepantel applied in isolation produced no measurable currents thereby ruling out an agonist action. When monepantel was continuously applied, it reduced the amplitude of acetylcholine induced currents in a concentration-dependent manner. In all three subtypes, monepantel acted as a non-competitive antagonist on the expressed receptors. ACR-16 from *A. suum* was particularly sensitive to monepantel inhibition (IC_{50} values: 1.6 ± 3.1 nM and 0.2 ± 2.3 μ M). We also investigated the effects of monepantel on muscle flaps isolated from adult *A. suum*. The drug did not significantly increase baseline tension when applied on its own. As with acetylcholine induced currents in the heterologously expressed receptors, contractions induced by acetylcholine were antagonized by monepantel. Further investigation revealed that the inhibition was a mixture of competitive and non-competitive antagonism. Our findings suggest that monepantel is active on multiple nAChR subtypes.

1. Introduction

Soil-Transmitted Helminth (STH) infections in humans and animals cause significant disease (morbidity & mortality) globally. At least 1.2 billion people suffer from STH infections, with an estimated at-risk population of 4.5 billion (Bethony et al., 2006; Brooker et al., 2006; Lammie et al., 2006). Control of these infections is heavily reliant on the use of anthelmintics as there are no effective vaccines and sanitation is often sub-optimal (Kaminsky et al., 2013). There are a limited number of drugs used to treat helminth infections (Keiser and Utzinger, 2008). Antinematodal (anthelmintic) drugs can be classified on the

basis of similarity in chemical structure; benzimidazoles, imidazothiazoles, tetrahydropyrimidines, macrocyclic lactones, amino-acetonitrile derivatives, spiroindoles and cyclooctadepsipeptides. The benzimidazoles, imidazothiazoles, tetrahydropyrimidines and macrocyclic lactones are older anthelmintic drug classes. Increasing reports of resistance to the 'older' anthelmintic drugs has encouraged the development of newer drug classes: amino-acetonitrile derivatives, spiroindoles and cyclooctadepsipeptides.

Zolvix[®] (Novartis Animal Health, Greensboro, NC, USA) is a recently developed anthelmintic for control of gastro-intestinal (GI) nematodes in sheep. It was first introduced in New Zealand in 2009, and contains

Abbreviations: mptl, monepantel; ach, acetylcholine; nAChR, nicotinic acetylcholine receptor; STH, Soil-Transmitted Helminth; *Asu*, *Ascaris suum*; *Ode*, *Oesophagostomum dentatum*; *Hco*, *Haemonchus contortus*; GI, gastro-intestinal; AADs, amino-acetonitrile derivatives; LGIC, ligand-gated ion channel; APF, *Ascaris* Perienteric Fluid; DMSO, dimethyl sulfoxide

* Corresponding author. 2058 College of Vet Med, 1800 Christensen Dr, Ames, IA 50011-1134, USA.

E-mail address: alanr@iastate.edu (A.P. Robertson).

¹ Contributed equally.

² Present address: Department of Industrial and Physical Pharmacy, School of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.

<https://doi.org/10.1016/j.ijpddr.2017.12.001>

Received 15 October 2017; Received in revised form 7 December 2017; Accepted 11 December 2017

Available online 16 December 2017

2211-3207/© 2017 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. Chemical structure of monepantel [N-[(2S)-2-cyano-1-[5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl]-4-(trifluoromethylsulfanyl)benzamide].

25 mg/ml monepantel (mptl) as the active ingredient (Fig. 1). Monepantel is the first member of the amino-acetonitrile derivative (AAD) group of anthelmintics. It has a wide range of activity against nematodes in sheep, including those resistant to benzimidazoles, imidazothiazoles and macrocyclic lactones (Ducray et al., 2008; Kaminsky et al., 2008a, 2008b). Disappointingly, resistance has developed in infected goats and sheep following treatment with monepantel. The first field report of monepantel resistance was observed in *Teladorsagia circumcincta* and *Trichostrongylus colubriformis* in goats and sheep on a farm in the lower North Island in New Zealand < 2 years after its initial use on that farm (Scott et al., 2013). Subsequent cases of resistance to monepantel have been reported for *H. contortus* in sheep (Mederos et al., 2014; Van den Brom et al., 2015). The emergence of field resistance to monepantel within very short periods following treatment underscores the pressing need to understand the full mode of action of the drug and thus possible mechanisms of resistance.

Monepantel has a site of action reported to involve ACR-23, a member of the DEG-3/DES-2 group of nicotinic acetylcholine receptors (nAChRs) (Lecova et al., 2014). Kaminsky et al. (2008a) showed AADs to cause hypercontraction of body wall muscles in *Caenorhabditis elegans* and *Haemonchus contortus*, leading to spastic paralysis and subsequent death of the worms. These authors further revealed *C. elegans* treated with AADs display molting deficits and characteristics of necrosis (Kaminsky et al., 2008a). Subsequent mutagenesis screens in *H. contortus* led to the identification of the nAChR subunit gene, *mptl-1* (*acr-23*), as a target for AADs (Rufener et al., 2009). Comparative genomics of all ligand-gated ion channel (LGIC) genes from different clades of nematodes reported nematode species lacking the ACR-23/MPTL-1 nAChR subunits to be insensitive to monepantel. On the contrary, nematode species having ACR-23/MPTL-1 were susceptible to monepantel, thus promoting ACR-23/MPTL-1 nAChR as a principal target for the AADs (Rufener et al., 2010b). To further elucidate the mode of action of monepantel, Rufener et al. (2010b) showed that monepantel on its own did not activate heterologously expressed *H. contortus* DEG-3/DES-2 receptors but acted as a type 2 positive allosteric modulator when co-applied with choline (Rufener et al., 2010a). In heterologously expressed *C. elegans* ACR-23 receptors, monepantel caused potentiation following activation by betaine (Peden et al., 2013). Monepantel also acted as a positive allosteric modulator of *H. contortus* MPTL-1 and *C. elegans* ACR-20 receptors at low concentrations (< 1 nM) but as a direct agonist at high concentrations (> 0.1 μM) (Baur et al., 2015).

Interestingly, a homolog of *C. elegans* *acr-23* is present in the *A. suum* genome (Jex et al., 2011). However, *A. suum* is not susceptible to monepantel treatment *in vivo* (Tritten et al., 2011). Our research seeks to advance knowledge on the mode of action of monepantel on nAChRs from Clade III (*A. suum*) and Clade V (*Oesophagostomum dentatum*) nematodes. This present study therefore is an investigation of the effects of monepantel on nAChRs that are widely and ubiquitously expressed in *A. suum* (*Asu-ACR-16*), and those involved in neurotransmission (pyrantel/tribendimidine sensitive and levamisole sensitive nAChRs) in *O. dentatum*. We find that monepantel also acts selectively as an antagonist on the nematode nAChRs we studied.

2. Materials and methods

2.1. *Xenopus* oocyte expression

All nAChR subunit and ancillary factor cRNAs from *A. suum* (*Asu-acr-16* and *Asu-ric-3*), *O. dentatum* (*Ode-unc-29*, *Ode-unc-38*, *Ode-unc-68* and *Ode-acr-8*) and *H. contortus* (*Hco-ric-3*, *Hco-unc-50* and *Hco-unc-74*) were prepared as previously described (Abongwa et al., 2016a; Buxton et al., 2014). Briefly, defolliculated *X. laevis* oocytes were obtained from Ecocyte Bioscience (Austin, TX, USA). A Nanoject II microinjector (Drummond Scientific, Broomall, PA, USA) was used to inject cRNA into the cytoplasm at the animal pole region of the oocytes. Homomeric nAChRs comprising *Asu-ACR-16* subunits were expressed by co-injecting 25 ng of *Asu-acr-16* with 5 ng of *Asu-ric-3* in a total volume of 50 nl in nuclease-free water. Heteromeric nAChRs from *O. dentatum* were expressed by co-injecting 1.8 ng of each subunit cRNA that make up the levamisole (*Ode-unc-29*, *Ode-unc-38*, *Ode-unc-68* and *Ode-acr-8*) or pyrantel/tribendimidine (*Ode-unc-29*, *Ode-unc-38* and *Ode-unc-63*) receptor with 1.8 ng of each *H. contortus* ancillary factor (*Hco-ric-3*, *Hco-unc-50* and *Hco-unc-74*) in a total volume of 36 nl in nuclease-free water. Injected oocytes were transferred to 96-well microtiter plates containing 200 μl incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂·2H₂O, 1 mM MgCl₂·6H₂O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U·ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin, pH 7.5) and incubated at 19 °C for 5–7 days to allow for functional receptor expression. Incubation solution was changed daily.

2.2. Two-electrode voltage-clamp electrophysiology

Currents produced by activation of expressed *Asu-ACR-16* and *Ode* levamisole sensitive and *Ode* pyrantel/tribendimidine sensitive receptors were recorded using the two-electrode voltage-clamp electrophysiology technique as previously described (Abongwa et al., 2016a; Buxton et al., 2014). 100 μM BAPTA-AM was added to the oocyte incubation solution about 4 h prior to recording to prevent activation of endogenous calcium-activated chloride currents during recording. Recordings were made using an Axoclamp 2B amplifier (Molecular Devices, Sunnyvale, CA, USA) and data acquired on a computer with Clampex 10.3 (Molecular Devices, Sunnyvale, CA, USA). For all experiments, oocytes were voltage-clamped at –60 mV. Microelectrodes for impaling oocytes were pulled using a Flaming/Brown horizontal electrode puller (Model P-97; Sutter Instruments, Novato, CA, USA). The microelectrodes were filled with 3 M KCl and their tips carefully broken with a piece of tissue paper to attain a resistance of 2–5 MΩ in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl₂·2H₂O and 5 mM HEPES, pH 7.3).

2.3. Muscle contraction assay

Adult *A. suum* were collected from the IMES slaughterhouse, Belgrade, Serbia and maintained in Locke's solution (155 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1.5 mM NaHCO₃ and 5 mM glucose) at 32 °C for 5 days. Locke's solution was changed daily. *Ascaris* muscle flaps for contraction studies were prepared as described in Trailović et al. (2015). Briefly, 1 cm muscle body flaps were prepared by dissecting the anterior 2–3 cm part of the worm. A force transducer in an experimental bath containing 20 ml APF (23 mM NaCl, 110 mM Na acetate, 24 mM KCl, 6 mM CaCl₂, 5 mM MgCl₂, 11 mM glucose, 5 mM HEPES, pH 7.6) and 0.1% DMSO and bubbled with nitrogen was attached to each muscle flap. The bath was maintained at 37 °C during which isometric contractions of each flap were monitored on a PC computer using a BioSmart interface and eLAB software (EIUnit, Belgrade). The system allows real time recording, display and analysis of experimental data. The preparation was allowed to equilibrate for 15 min under an initial tension of 0.5 g after which acetylcholine (1–100 μM) in the absence and presence of monepantel (1–30 μM) was applied to the preparation.

2.4. Drugs

Acetylcholine was purchased from Sigma-Aldrich (St Louis, MO, USA). Zolvix (monepantel 25 mg/ml) was a gift from Dr Michael Kimber (Iowa State University, Ames, IA). Acetylcholine was dissolved in either APF or oocyte recording solution. Monepantel was dissolved in DMSO such that the final DMSO concentration did not exceed 0.1%. All other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) or Fisher Scientific (Hampton, NH, USA).

2.5. Data analysis

2.5.1. Electrophysiology

Electrophysiology data was measured with Clampfit 10.3 (Molecular devices, Sunnyvale CA, USA) and analyzed with GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). All concentration-response experiments began with a 10 s application of 100 μM acetylcholine. Increasing concentrations of acetylcholine (0.1–100 μM) were applied for 10 s at ~ 2 min intervals. For experiments using monepantel, an initial 10 s application of 100 μM acetylcholine was followed after 2 min by continuous perfusion of a single concentration of monepantel (0.3 nM - 30 μM); for the rest of the experiment 10 s applications of acetylcholine (0.3–100 μM) were used at ~ 2 min intervals in the presence of monepantel. Responses to each acetylcholine concentration were normalized to the initial control 100 μM acetylcholine responses and expressed as mean \pm s.e.m. Concentration-response relationships (for each oocyte) were analyzed by fitting log concentration-response data points with the Hill equation as previously described (Boulin et al., 2008). % inhibition for monepantel was calculated using $100-R_{\text{max}}$ for each experiment and plotted as mean \pm s.e.m. on the concentration-inhibition plots. IC_{50} 's were calculated as previously described (Zheng et al., 2016). We used one-way ANOVA to test for statistical differences among treatment groups. If the group means were statistically different ($p < .05$), we used the Tukey multiple comparison test to determine significant differences between groups.

2.5.2. Muscle contraction

Isometric contractions of each *Ascaris* muscle flap in the absence and presence of monepantel were monitored on a PC computer using eLAB software (EIUnit, Belgrade). GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used to analyze the data. Responses to each acetylcholine concentration in the absence and presence of monepantel were expressed as mean \pm s.e.m. Single concentration-response relationships were fitted to the data as described in Section 2.5.1.

3. Results

3.1. Effects of monepantel on *Asu*-ACR-16

Asu-ACR-16 is a homomeric nAChR comprising of *Asu*-ACR-16 subunits (Abongwa et al., 2016a). This receptor subtype requires only the ancillary factor *Asu*-RIC-3 for functional expression in *Xenopus* oocytes. ACR-16 is nicotine sensitive, but levamisole insensitive, and is commonly referred to as the nicotine subtype nAChR (Abongwa et al., 2016a; Ballivet et al., 1996; Raymond et al., 2000; Sattelle et al., 2009). We tested the effects of different monepantel concentrations (0.3 nM - 1 μM) on *Asu*-ACR-16 responses to acetylcholine. For control experiments, each acetylcholine concentration from 0.3 to 100 μM was applied for 10s, Fig. 2A. To test the effects of monepantel, 100 μM acetylcholine was first applied for 10s as control, followed by a 2 min wash, then perfusion with monepantel, after which acetylcholine applications were repeated in the presence of monepantel, Fig. 2B. For both control and test experiments, a 2 min wash period was applied between drug applications. Monepantel applied on its own did not cause activation of




Fig. 2. Inhibitory effects of monepantel on *Asu*-ACR-16 (nicotine sensitive receptors). (A) Sample traces for two-electrode voltage-clamp recording for oocyte responses to acetylcholine for oocytes expressing *Asu*-ACR-16 subtype nAChR. (B) Sample traces for two-electrode voltage-clamp recording for oocyte responses to acetylcholine in the presence of 1 μM monepantel. (C) Concentration-response plots for acetylcholine in the absence and presence of monepantel. Control acetylcholine ($n = 4$, black); in the presence of 0.3 nM monepantel ($n = 4$, light blue); 3 nM monepantel ($n = 4$, light purple); 30 nM monepantel ($n = 4$, orange), 0.1 μM monepantel ($n = 5$, olive green), 0.3 μM monepantel ($n = 4$, purple), 0.5 μM monepantel ($n = 4$, pink) and 1 μM monepantel ($n = 4$, green). (D) Bar chart showing mean \pm s.e.m. ($n = 4-5$) for R_{max} for acetylcholine and monepantel. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Asu-ACR-16, eliminating agonist actions on this receptor subtype. When co-applied with acetylcholine, monepantel caused a concentration-dependent inhibition of *Asu*-ACR-16 responses to acetylcholine. Fig. 2C shows concentration-response plots for these experiments. Monepantel did not change the EC_{50} but did significantly reduce R_{max} , Fig. 2C and D, implying non-competitive antagonism. EC_{50} and R_{max} values for these observations are shown in Table 1.

Table 1
Effect of monepantel on acetylcholine EC_{50} and R_{max} values for *Asu*-ACR-16.

	EC_{50} (mean \pm s.e.m., n)	R_{max} (mean \pm s.e.m., n)
Acetylcholine	5.9 \pm 0.3 μ M, n = 4	97.5 \pm 1.2%, n = 4
+ 0.3 nM monepantel	7.3 \pm 0.0 μ M, n = 4	91.4 \pm 6.6%, n = 4
+ 3 nM monepantel	7.1 \pm 0.1 μ M, n = 4	75.3 \pm 5.1%, n = 4
+ 30 nM monepantel	6.8 \pm 0.8 μ M, n = 4	63.6 \pm 4.2%, n = 4
+ 0.1 μ M monepantel	9.2 \pm 1.0 μ M, n = 5	61.6 \pm 5.8%, n = 5
+ 0.3 μ M monepantel	6.9 \pm 0.2 μ M, n = 4	38.2 \pm 0.8%, n = 4
+ 0.5 μ M monepantel	7.0 \pm 0.5 μ M, n = 4	32.5 \pm 3.2%, n = 4
+ 1 μ M monepantel	9.1 \pm 1.3 μ M, n = 4	19.9 \pm 0.5%, n = 4

3.2. Effects of monepantel on expressed *Ode* pyrantel/tribendimidine receptors

Ode pyrantel/tribendimidine receptors were described by Buxton et al. (2014) to comprise of the nAChR subunits *Ode*-UNC-29, *Ode*-UNC-38 and *Ode*-UNC-63. *Ode* pyrantel/tribendimidine receptors require all 3 ancillary factors *Hco*-RIC-3, *Hco*-UNC-50 and *Hco*-UNC-74 from *H. contortus* for functional expression in oocytes. To investigate the effects of monepantel on expressed *Ode* pyrantel/tribendimidine receptors, we used the same experimental protocol described for *Asu*-ACR-16 receptors in Section 3.1. Fig. 3C shows concentration-response plots for these experiments. Monepantel alone did not activate *Ode* pyrantel/tribendimidine receptors ruling out an agonist action. When co-applied with acetylcholine, features of non-competitive antagonism (no change in EC_{50} , reduction in R_{max}) were seen for *Ode* pyrantel/tribendimidine receptors, Fig. 3C and D. Table 2 shows EC_{50} and R_{max} values for these experiments.

3.3. Effects of monepantel on expressed *Ode* levamisole receptors

Previous studies showed the nAChR subunits *Ode*-UNC-29, *Ode*-UNC-38, *Ode*-UNC-63 and *Ode*-ACR-8 are required to express the *Ode* levamisole sensitive receptors in *Xenopus* oocytes (Buxton et al., 2014). This was in accordance with previous work by Boulin et al. (2011) who expressed functional levamisole receptors in *Xenopus* oocytes when these oocytes were injected with *Hco*-UNC-29, *Hco*-UNC-38, *Hco*-UNC-63 and *Hco*-ACR-8 from *H. contortus*. The levamisole receptors required all 3 ancillary factors *Hco*-RIC-3, *Hco*-UNC-50 and *Hco*-UNC-74 from *H. contortus* for its functional expression in oocytes (Boulin et al., 2008, 2011; Buxton et al., 2014). To investigate the effects of monepantel on expressed *Ode* levamisole receptors, we used the same experimental protocol described for *Asu*-ACR-16 receptors in Section 3.1. The monepantel concentrations tested on levamisole receptors were from 1 to 30 μ M. Sample traces and concentration-response plots for these experiments are shown in Fig. 4A, B, & C. Again, monepantel applied alone failed to activate the *Ode* levamisole receptors, demonstrating no agonist action. As expected for a non-competitive antagonist, monepantel did not produce any significant change in EC_{50} but did cause a significant reduction in R_{max} as shown in Fig. 4C and D. EC_{50} and R_{max} values for these experiments are reported in Table 3.

3.4. Effects of monepantel on *Ascaris* body muscle flaps

The results we obtained for expressed nicotine (*Asu*-ACR-16), *Ode* pyrantel/tribendimidine (*Ode*-UNC-29:*Ode*-UNC-38:*Ode*-UNC-63) and *Ode* levamisole (*Ode*-UNC-29:*Ode*-UNC-38:*Ode*-UNC-63:*Ode*-ACR-8) subtype nAChRs which we describe in Sections 3.1, 3.2 and 3.3, encouraged us to investigate the *in vivo* effects of monepantel on *Ascaris* muscle. Fig. 5A shows representative traces of the effects of adding increasing concentrations of acetylcholine in the absence and presence of monepantel on isometric contractions of an *Ascaris* body flap preparation. Application of increasing concentrations of acetylcholine from 1 to 100 μ M produced concentration-dependent contraction responses




Fig. 3. Inhibitory effects of monepantel on *Ode* pyrantel/tribendimidine preferring nAChRs. (A) Sample traces for two-electrode voltage-clamp recording for oocyte responses to acetylcholine for oocytes expressing *Ode* pyrantel/tribendimidine subtype nAChR. (B) Sample traces for two-electrode voltage-clamp recording for oocyte responses to acetylcholine in the presence of 0.3 μ M monepantel. (C) Concentration-response plots for acetylcholine in the absence and presence of monepantel. Control acetylcholine (n = 4, black); in the presence of 0.3 μ M monepantel (n = 5, purple); 1 μ M monepantel (n = 4, green); 3 μ M monepantel (n = 4, red) and 10 μ M monepantel (n = 4, blue). (D) Bar chart showing mean \pm s.e.m. (n = 4–5) for R_{max} for acetylcholine and monepantel. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Table 2
Effect of monepantel on acetylcholine EC_{50} and R_{max} values for *Ode* pyrantel/tribendimidine receptors.

	EC_{50} (mean \pm s.e.m., n)	R_{max} (mean \pm s.e.m., n)
Acetylcholine	11.3 \pm 1.3 μ M, n = 4	118.2 \pm 4.5%, n = 4
+ 0.3 μ M monepantel	13.2 \pm 1.4 μ M, n = 5	69.4 \pm 3.5%, n = 5
+ 1 μ M monepantel	10.4 \pm 1.0 μ M, n = 4	56.8 \pm 4.8%, n = 4
+ 3 μ M monepantel	12.9 \pm 1.5 μ M, n = 4	29.0 \pm 0.9%, n = 4
+ 10 μ M monepantel	14.5 \pm 1.6 μ M, n = 4	13.4 \pm 0.6%, n = 4




Fig. 4. Monepantel inhibits *Ode* levamisole preferring receptors. (A) Sample traces for two-electrode voltage-clamp recording for oocyte responses to acetylcholine for oocytes expressing *Ode* levamisole subtype nAChR. (B) Sample traces for two-electrode voltage-clamp recording for oocyte responses to acetylcholine in the presence of 3 μ M monepantel. (C) Concentration-response plots for acetylcholine in the absence and presence of monepantel. Control acetylcholine (n = 4, black); in the presence of 1 μ M monepantel (n = 4, green); 3 μ M monepantel (n = 4, red); 10 μ M monepantel (n = 4, blue) and 30 μ M monepantel (n = 5, grey). (D) Bar chart showing mean \pm s.e.m. (n = 4–5) for R_{max} for acetylcholine and monepantel. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Table 3

Effect of monepantel on acetylcholine EC_{50} and R_{max} values for *Ode* levamisole receptors.

	EC_{50} (mean \pm s.e.m., n)	R_{max} (mean \pm s.e.m., n)
Acetylcholine	2.7 \pm 0.4 μ M, n = 4	108.8 \pm 1.0%, n = 4
+ 1 μ M monepantel	3.8 \pm 0.4 μ M, n = 4	87.9 \pm 1.2%, n = 4
+ 3 μ M monepantel	2.7 \pm 0.4 μ M, n = 4	69.3 \pm 3.2%, n = 4
+ 10 μ M monepantel	2.2 \pm 0.4 μ M, n = 4	25.0 \pm 1.4%, n = 4
+ 30 μ M monepantel	1.8 \pm 0.3 μ M, n = 5	3.9 \pm 0.1%, n = 5

which were inhibited by monepantel in a concentration-dependent manner. Monepantel on its own did not produce any significant change in baseline tension. Washing reversed the inhibition caused by monepantel to near control levels. Concentration-response plots (mean \pm




Fig. 5. Inhibition of *Ascaris suum* muscle flap contractions by monepantel. (A) Isometric contractions of *A. suum* muscle flap following application of increasing acetylcholine concentrations and antagonism by 10 μ M (blue bar) and 30 μ M (grey bar) monepantel. (B) Concentration-contraction response plots for acetylcholine showing mean \pm s.e.m. bars. Control acetylcholine (n = 11, black); in the presence of 1 μ M monepantel (n = 6, green), 3 μ M monepantel (n = 6, red), 10 μ M monepantel (n = 5, blue) and 30 μ M monepantel (n = 5, grey). (C) Inhibition curve plotted as mean \pm s.e.m. (n = 4–5) maximum response versus concentration of monepantel and Hill equation fit with an IC_{50} of 1.6 \pm 3.1 nM and 0.2 \pm 2.3 μ M for *Asu*-ACR-16, 1.7 \pm 0.7 μ M for *Ode* pyrantel/tribendimidine, and 5.0 \pm 0.5 μ M for *Ode* levamisole receptors. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Table 4

Effect of monepantel on acetylcholine EC_{50} and R_{max} values for *A. suum* muscle flaps (n = 5–11 for each data point fitted).

	EC_{50} (log $EC_{50} \pm$ s.e.m.)	R_{max} (mean \pm s.e.m.)
Acetylcholine	5.3 μ M (0.7 \pm 0.5)	1.7 \pm 0.4 g
+ 1 μ M monepantel	12.5 μ M (1.1 \pm 0.6)	1.8 \pm 1.3 g
+ 3 μ M monepantel	16.0 μ M (1.2 \pm 0.3)	1.1 \pm 0.3 g
+ 10 μ M monepantel	18.4 μ M (1.3 \pm 0.4)	1.1 \pm 0.5 g
+ 30 μ M monepantel	23.5 μ M (1.4 \pm 0.7)	0.5 \pm 0.4 g

s.e.m.) for acetylcholine and monepantel are shown in Fig. 5B. 1 μ M monepantel produced a significant reduction in the maximum response, R_{max} and also shifted the EC_{50} to the right. Increasing the concentration of monepantel to 3, 10 and 30 μ M further reduced the R_{max} and caused a further right-shift in the EC_{50} , characteristic of a mixture of competitive and non-competitive antagonism. The activity of monepantel on *Ascaris* muscle flaps was rather interesting, as previous authors have showed monepantel (600 mg/kg) to lack *in vivo* activity against *A. suum* (Tritten et al., 2011). Table 4 shows EC_{50} and R_{max} values for acetylcholine alone and in the presence of 1–30 μ M monepantel.

In an effort to infer what nAChR subtypes monepantel maybe acting on, we generated inhibition plots for *Asu*-ACR-16, *Ode* pyrantel/tribendimidine and *Ode* levamisole subtype nAChRs, Fig. 5C and Table 5. The inhibition caused by monepantel (Fig. 5C) on *Asu*-ACR-16 had 2 components, one with an IC_{50} of 1.6 \pm 3.1 nM, and the other with an IC_{50} of 0.2 \pm 2.3 μ M, suggesting the likelihood of more than one

Table 5
 IC_{50} values for monepantel on expressed nAChRs from *A. suum* and *O. dentatum*.

	IC_{50} (mean \pm s.e.m., n)
<i>Asu</i> -ACR-16 nAChR	1.6 \pm 3.1 nM; 0.2 \pm 2.3 μ M, n = 4
<i>Ode</i> pyrantel/tribendimidine nAChRs	1.7 \pm 0.7 μ M, n = 4
<i>Ode</i> levamisole nAChRs	5.0 \pm 0.5 μ M, n = 4

binding site for monepantel on *Asu*-ACR-16. The IC_{50} monepantel for *Ode* pyrantel/tribendimidine receptors (1.7 \pm 0.7 μ M) was seen to be lower than that for the *Ode* levamisole receptors (5.0 \pm 0.5 μ M). The *Ode* pyrantel/tribendimidine receptors appear to be more sensitive to monepantel than the *Ode* levamisole receptors. When we compare these results with that of the *in vivo* effects shown in Fig. 5B, monepantel appears to be acting on a mixture of the *Asu*-ACR-16, *Ode* pyrantel/tribendimidine and *Ode* levamisole nAChRs.

4. Discussion

4.1. Non-competitive antagonism of monepantel on expressed *A. suum* and *O. dentatum* receptors

In contrast to the positive allosteric modulatory effects of monepantel on DEG-3/DES-2 nAChRs, we found monepantel to produce non-competitive inhibition of *Asu*-ACR-16 and *Ode* levamisole sensitive and *Ode* pyrantel/tribendimidine sensitive nAChRs. These observations were consistent with results obtained from our muscle contraction assay. In all cases, monepantel produced no change in EC_{50} but a significant reduction in R_{max} , an observation which was seen to be concentration-dependent. Of all three receptor subtypes expressed in *Xenopus* oocytes, *Asu*-ACR-16 was most sensitive to monepantel as reflected by its IC_{50} values of 1.6 \pm 3.1 nM and 0.2 \pm 2.3 μ M. This was followed by the *Ode* pyrantel/tribendimidine receptor with an of IC_{50} of 1.7 \pm 0.7 μ M, and the *Ode* levamisole receptor with an IC_{50} of 5.0 \pm 0.5 μ M. Monepantel had a potent inhibitory effect on *Asu*-ACR-16, involving 2 components: one in which the maximum inhibition was only 40%, giving an IC_{50} value of 1.6 \pm 3.1 nM and the other in which the maximum inhibition nearly reached 100%, giving an IC_{50} value of 0.2 \pm 2.3 μ M. These observations suggest that monepantel also acts via negative allosteric modulation, involving more than one binding site as is the case with abamectin and other negative allosteric modulators of nAChRs (Abongwa et al., 2016b; Zheng et al., 2016).

4.2. Mixed antagonism of monepantel on *A. suum* muscle flap

Monepantel causes hypercontraction of both *C. elegans* and *H. contortus* (Kaminsky et al., 2008a). In our electrophysiology experiments, monepantel produced an inhibitory effect on inward currents induced by acetylcholine. To further characterize the inhibition by monepantel, we tested different concentrations of monepantel in the presence of acetylcholine on *A. suum* muscle flaps. With all concentrations tested, monepantel produced a significant concentration-dependent reduction in R_{max} , and a right-shift in EC_{50} . In sharp contrast to the effects on *C. elegans* and *H. contortus* this indicates monepantel is a mixed antagonist of *Ascaris* muscle contraction. These results are likely due to the mixed nAChR populations on nematode muscle (Robertson et al., 1999, 2002; Qian et al., 2006). *Asu*-ACR-16 is extremely sensitive to monepantel; the observed shift in EC_{50} in the muscle flap experiment is likely due to the almost complete inhibition of *Asu*-ACR-16 at the concentrations tested in the muscle. The non-competitive aspect of the inhibition is in agreement with the results obtained from the *Ode* levamisole sensitive and *Ode* pyrantel/tribendimidine sensitive receptors.

4.3. Conclusion

Our results indicate that monepantel acts as an antagonist of *Ascaris* muscle contraction, and as a non-competitive antagonist, with subtype selective effects, of expressed nAChR subtypes from *A. suum* (Clade III) and *O. dentatum* (Clade V). Non-competitive antagonism of monepantel on expressed nAChRs which we show in our research adds to the reported mode of action of monepantel as a positive allosteric modulator of expressed receptors of the DEG-3/DES-2 group of nAChRs. Thus, illustrating the complexity of the mode of action of the drug; involving more than one target site. Detailed understanding of the mode of action of antinematodal drugs is necessary, especially when considered for use in combination therapy/products, an approach proven to be highly effective for parasite control. As with many pharmacological agents we find that the mode of action of monepantel is complex and the drug is active on multiple nAChR subtypes.

Statement of conflict of interest

None identified.

Acknowledgments

We would like to acknowledge NIH R21AI092185-01A1 to APR, NIH RO1 AI047194-15 and the E. A. Benbrook Foundation for Pathology and Parasitology to RJM, Schlumberger Foundation Faculty for the Future Fellowship to MA and NIH T35 OD 012199-13 to JGT. We would also like to thank Dr Michael Kimber of Iowa State University for the gift of Zolvix (monepantel).

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.ijpddr.2017.12.001>.

References

- Abongwa, M., Buxton, S.K., Courtot, E., Charvet, C.L., Neveu, C., McCoy, C.J., Verma, S., Robertson, A.P., Martin, R.J., 2016a. Pharmacological profile of *Ascaris suum* ACR-16, a new homomeric nicotinic acetylcholine receptor widely distributed in *Ascaris* tissues. *Br. J. Pharmacol.* 173, 2463–2477.
- Abongwa, M., Buxton, S.K., Robertson, A.P., Martin, R.J., 2016b. Curiouser and curiouser: the macrocyclic lactone, abamectin, is also a potent inhibitor of pyrantel/tribendimidine nicotinic acetylcholine receptors of gastro-intestinal worms. *PLoS One* 11, e0146854.
- Ballivet, M., Alliod, C., Bertrand, S., Bertrand, D., 1996. Nicotinic acetylcholine receptors in the nematode *Caenorhabditis elegans*. *J. Mol. Biol.* 258, 261–269.
- Baur, R., Beech, R., Sigel, E., Rufener, L., 2015. Monepantel irreversibly binds to and opens *Haemonchus contortus* MPTL-1 and *Caenorhabditis elegans* ACR-20 receptors. *Mol. Pharmacol.* 87, 96–102.
- Bethony, J., Brooker, S., Albonico, M., Geiger, S.M., Loukas, A., Diemert, D., Hotez, P.J., 2006. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. *Lancet* 367, 1521–1532.
- Boulin, T., Fauvin, A., Charvet, C.L., Cortet, J., Cabaret, J., Bessereau, J.L., Neveu, C., 2011. Functional reconstitution of *Haemonchus contortus* acetylcholine receptors in *Xenopus* oocytes provides mechanistic insights into levamisole resistance. *Br. J. Pharmacol.* 164, 1421–1432.
- Boulin, T., Gielen, M., Richmond, J.E., Williams, D.C., Paoletti, P., Bessereau, J.L., 2008. Eight genes are required for functional reconstitution of the *Caenorhabditis elegans* levamisole-sensitive acetylcholine receptor. *Proc Natl Acad Sci U S A* 105, 18590–18595.
- Brooker, S., Clements, A.C., Bundy, D.A., 2006. Global epidemiology, ecology and control of soil-transmitted helminth infections. *Adv. Parasitol.* 62, 221–261.
- Buxton, S.K., Charvet, C.L., Neveu, C., Cabaret, J., Cortet, J., Peineau, N., Abongwa, M., Courtot, E., Robertson, A.P., Martin, R.J., 2014. Investigation of acetylcholine receptor diversity in a nematode parasite leads to characterization of tribendimidine and derquantel-sensitive nAChRs. *PLoS Pathog.* 10, e1003870.
- Ducray, P., Gauvry, N., Pautrat, F., Goebel, T., Fruechtel, J., Desaulles, Y., Weber, S.S., Bouvier, J., Wagner, T., Froelich, O., Kaminsky, R., 2008. Discovery of amino-acetonitrile derivatives, a new class of synthetic anthelmintic compounds. *Bioorg. Med. Chem. Lett.* 18, 2935–2938.
- Jex, A.R., Liu, S., Li, B., Young, N.D., Hall, R.S., Li, Y., Yang, L., Zeng, N., Xu, X., Xiong, Z., Chen, F., Wu, X., Zhang, G., Fang, X., Kang, Y., Anderson, G.A., Harris, T.W., Campbell, B.E., Vlaminck, J., Wang, T., Cantacessi, C., Schwarz, E.M., Ranganathan,

- S., Geldhof, P., Nejsum, P., Sternberg, P.W., Yang, H., Wang, J., Wang, J., Gasser, R.B., 2011. *Ascaris suum* draft genome. *Nature* 479, 529–533.
- Kaminsky, R., Ducray, P., Jung, M., Clover, R., Rufener, L., Bouvier, J., Weber, S.S., Wenger, A., Wieland-Berghausen, S., Goebel, T., Gauvry, N., Pautrat, F., Skripsky, T., Froelich, O., Komoin-Oka, C., Westlund, B., Sluder, A., Maser, P., 2008a. A new class of anthelmintics effective against drug-resistant nematodes. *Nature* 452, 176–180.
- Kaminsky, R., Gauvry, N., Schorderet Weber, S., Skripsky, T., Bouvier, J., Wenger, A., Schroeder, F., Desaulles, Y., Hotz, R., Goebel, T., Hosking, B.C., Pautrat, F., Wieland-Berghausen, S., Ducray, P., 2008b. Identification of the amino-acetonitrile derivative monepantel (AAD 1566) as a new anthelmintic drug development candidate. *Parasitol. Res.* 103, 931–939.
- Kaminsky, R., Rufener, L., Bouvier, J., Lizundia, R., Schorderet Weber, S., Sager, H., 2013. Worms—a “license to kill”. *Vet. Parasitol.* 195, 286–291.
- Keiser, J., Utzinger, J., 2008. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. *J. Am. Med. Assoc.* 299, 1937–1948.
- Lammie, P.J., Fenwick, A., Utzinger, J., 2006. A blueprint for success: integration of neglected tropical disease control programmes. *Trends Parasitol.* 22, 313–321.
- Lecova, L., Stuchlikova, L., Prchal, L., Skalova, L., 2014. Monepantel: the most studied new anthelmintic drug of recent years. *Parasitology* 141, 1686–1698.
- Mederos, A.E., Ramos, Z., Banchemo, G.E., 2014. First report of monepantel *Haemonchus contortus* resistance on sheep farms in Uruguay. *Parasites Vectors* 7, 598.
- Peden, A.S., Mac, P., Fei, Y.J., Castro, C., Jiang, G., Murfitt, K.J., Miska, E.A., Griffin, J.L., Ganapathy, V., Jorgensen, E.M., 2013. Betaine acts on a ligand-gated ion channel in the nervous system of the nematode *C. elegans*. *Nat. Neurosci.* 16, 1794–1801.
- Qian, H., Martin, R.J., Robertson, A.P., 2006. Pharmacology of N-, L-, and B-subtypes of nematode nAChR resolved at the single-channel level in *Ascaris suum*. *Faseb. J.* 20, 2606–2608.
- Raymond, V., Mongan, N.P., Sattelle, D.B., 2000. Anthelmintic actions on homomer-forming nicotinic acetylcholine receptor subunits: chicken alpha7 and ACR-16 from the nematode *Caenorhabditis elegans*. *Neuroscience* 101, 785–791.
- Robertson, A.P., Bjorn, H.E., Martin, R.J., 1999. Resistance to levamisole resolved at the single-channel level. *Faseb. J.* 13, 749–760.
- Robertson, A.P., Clark, C.L., Burns, T.A., Thompson, D.P., Geary, T.G., Trailovic, S.M., Martin, R.J., 2002. Paraherquamide and 2-deoxy-paraherquamide distinguish cholinergic receptor subtypes in *Ascaris* muscle. *J. Pharmacol. Exp. Therapeut.* 302, 853–860.
- Rufener, L., Baur, R., Kaminsky, R., Maser, P., Sigel, E., 2010a. Monepantel allosterically activates DEG-3/DES-2 channels of the gastrointestinal nematode *Haemonchus contortus*. *Mol. Pharmacol.* 78, 895–902.
- Rufener, L., Keiser, J., Kaminsky, R., Maser, P., Nilsson, D., 2010b. Phylogenomics of ligand-gated ion channels predicts monepantel effect. *PLoS Pathog.* 6, e1001091.
- Rufener, L., Maser, P., Roditi, I., Kaminsky, R., 2009. *Haemonchus contortus* acetylcholine receptors of the DEG-3 subfamily and their role in sensitivity to monepantel. *PLoS Pathog.* 5, e1000380.
- Sattelle, D.B., Buckingham, S.D., Akamatsu, M., Matsuda, K., Pienaar, I.S., Jones, A.K., Sattelle, B.M., Almond, A., Blundell, C.D., 2009. Comparative pharmacology and computational modelling yield insights into allosteric modulation of human alpha7 nicotinic acetylcholine receptors. *Biochem. Pharmacol.* 78, 836–843.
- Scott, I., Pomroy, W.E., Kenyon, P.R., Smith, G., Adlington, B., Moss, A., 2013. Lack of efficacy of monepantel against *Teladorsagia circumcincta* and *Trichostrongylus colubriformis*. *Vet. Parasitol.* 198, 166–171.
- Trailović, S.M., Marjanović, D.J.S., Nedeljković, Trailović, J., Robertson, A.P., Martin, R.J., 2015. Interaction of carvacrol with the *Ascaris suum* nicotinic acetylcholine receptors and gamma-aminobutyric acid receptors, potential mechanism of antinematodal action. *Parasitol. Res.* 114, 3059–3068.
- Tritten, L., Silbereisen, A., Keiser, J., 2011. In vitro and in vivo efficacy of Monepantel (AAD 1566) against laboratory models of human intestinal nematode infections. *PLoS Neglected Trop. Dis.* 5, e1457.
- Van den Brom, R., Moll, L., Kappert, C., Vellema, P., 2015. *Haemonchus contortus* resistance to monepantel in sheep. *Vet. Parasitol.* 209, 278–280.
- Zheng, F., Robertson, A.P., Abongwa, M., Yu, E.W., Martin, R.J., 2016. The *Ascaris suum* nicotinic receptor, ACR-16, as a drug target: four novel negative allosteric modulators from virtual screening. *Int J Parasitol Drugs Drug Resist* 6, 60–73.